USA - NASDAQ:ZLAB - US98887Q1040 - ADR
The current stock price of ZLAB is 28.74 USD. In the past month the price decreased by -13.3%. In the past year, price decreased by -11.21%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.91 | 409.95B | ||
AMGN | AMGEN INC | 13.91 | 163.30B | ||
GILD | GILEAD SCIENCES INC | 15.91 | 152.76B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.74 | 107.45B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 64.39B | ||
REGN | REGENERON PHARMACEUTICALS | 12.64 | 61.13B | ||
ARGX | ARGENX SE - ADR | 92.23 | 52.30B | ||
INSM | INSMED INC | N/A | 35.49B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.15 | 34.99B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.95B | ||
NTRA | NATERA INC | N/A | 25.89B | ||
BIIB | BIOGEN INC | 9.16 | 21.50B |
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The firm has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
ZAI LAB LTD-ADR
Building B, 899 Halei Road, Pudong
Shanghai SHANGHAI 201210 CN
CEO: Samantha (Ying) Du
Employees: 1869
Phone: 862161632588
The current stock price of ZLAB is 28.74 USD. The price increased by 1.59% in the last trading session.
The exchange symbol of ZAI LAB LTD-ADR is ZLAB and it is listed on the Nasdaq exchange.
ZLAB stock is listed on the Nasdaq exchange.
13 analysts have analysed ZLAB and the average price target is 33.97 USD. This implies a price increase of 18.21% is expected in the next year compared to the current price of 28.74. Check the ZAI LAB LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ZAI LAB LTD-ADR (ZLAB) has a market capitalization of 3.20B USD. This makes ZLAB a Mid Cap stock.
ZAI LAB LTD-ADR (ZLAB) currently has 1869 employees.
ZAI LAB LTD-ADR (ZLAB) has a support level at 28.29 and a resistance level at 32.39. Check the full technical report for a detailed analysis of ZLAB support and resistance levels.
The Revenue of ZAI LAB LTD-ADR (ZLAB) is expected to grow by 43.01% in the next year. Check the estimates tab for more information on the ZLAB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ZLAB does not pay a dividend.
ZAI LAB LTD-ADR (ZLAB) will report earnings on 2025-11-11.
ZAI LAB LTD-ADR (ZLAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.96).
The outstanding short interest for ZAI LAB LTD-ADR (ZLAB) is 4.74% of its float. Check the ownership tab for more information on the ZLAB short interest.
ChartMill assigns a fundamental rating of 3 / 10 to ZLAB. Both the profitability and financial health of ZLAB have multiple concerns.
Over the last trailing twelve months ZLAB reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS increased by 33.33% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -18.26% | ||
ROE | -26.84% | ||
Debt/Equity | 0.22 |
13 analysts have analysed ZLAB and the average price target is 33.97 USD. This implies a price increase of 18.21% is expected in the next year compared to the current price of 28.74.
For the next year, analysts expect an EPS growth of 42.88% and a revenue growth 43.01% for ZLAB